NCT05574881进行中（未招募）1 期
A Prospective, Single Center, Phase II Trial of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects voluntarily joined the study, signed informed consent, and had good compliance.
- •Postmenopausal or premenopausal perimenopausal female patients aged ≥ 18 years, Meet one of the following:
- •Previous bilateral oophorectomy, or age ≥ 60 years; or Age <60, natural postmenopausal state (defined as regular months for at least 12 consecutive months After spontaneous cessation and no other pathological or physiological reasons), E2 and follicle stimulating hormone (FSH) in menopause Post-level; or Pre-menopausal or perimenopausal female patients can also be included, but must be willing to receive treatment with luteinizing hormone releasing hormone (LHRH) agonists;
- •Patients with HR+/HER2+ recurrent or metastatic breast cancer confirmed by histopathology； HER2 positivity is defined by standard of 3+ staining by immunohistochemical staining (IHC) or positive for in situ hybridization (ISH)； Estrogen receptor (ER) or Progesterone receptor (PR) positive is defined as the percentage of cells positive for ER or PR expression ≥ 10%； Local recurrence needs to be confirmed by the physician that is unresectable
- •At least one extracranial measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.
- •No systemic treatment in metastatic setting. At least 12-month interval between the time of last dose of trastuzumab in adjuvant treatment and the date of diagnosis with recurrent or metastatic breast cancer
- •Had received endocrine therapy in adjuvant setting.
- •Eastern Cooperative Oncology Group Performance Status of 0-
- •Life expectancy ≥ 12 weeks.
- •Adequate function of major organs meets the following requirements (no blood components and cell growth factors have been used within 14 days before randomization):
- •Neutrophils ≥ 1.5×10^9/L， Platelets ≥ 100×10^9/L， Hemoglobin ≥ 90g/L， Total bilirubin≤ 1.5 × the upper limit of normal (ULN)， Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN， blood urea nitrogen(BUN) and Cr ≤ 1.5 × ULN， Left ventricular ejection fraction (LVEF) ≥ 50%， QTcF(Fridericia correction) ≤ 470 ms， International normalized ratio(INR)≤1.5 × ULN， activated partial thromboplastin time(APTT) ≤ 1.5 × ULN
排除标准
- •Meningeal metastasis or active brain parenchymal metastasis. Patients with clinically stable brain parenchymal metastases can be included, including asymptomatic brain metastases that have not received local treatment; or patients who have previously received central nervous system metastasis therapy (radiotherapy or surgery), if imaging confirms that stability has been maintained for at least 4 weeks, and have stopped symptomatic treatment (including hormones and mannitol, etc.) for more than 2 weeks
- •Visceral crisis.
- •Previously received any CDK4/6 inhibitor treatment.
- •Inability to swallow, intestinal obstruction or other factors affecting the administration and absorption of the drug.
- •Patients with other malignant tumors within 5 years or at the same time( except for cured skin basal cell carcinoma and cervical carcinoma in situ).
- •Have undergone major surgical procedures or significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgery.
- •Pregnant women, lactating female, or women of childbearing age who are unwilling to take effective contraceptive measures.
- •Have a history of allergies to the drug components of this regimen.
- •Patients with active HBV and HCV infection; stable hepatitis B after drug treatment (HBV virus copy number is higher than the upper limit of reference value) and cured hepatitis C patients (HCV virus copy number exceeds the lower limit of detection method).
- •History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, history of organ transplantation.
- •History of cardiac dysfunction, include (1)angina (2)clinical significant arrythmia or require drug intervention (3)myocardial infarction (4)heart failure (5) other cardiac dysfunction (judged by the physician); any cardiac or nephric abnormal ≥ grade 2 found in screening.
- •Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.
- •Childbearing female who refuses to accept any contraception practice.
- •Determined by the physician, any serious coexisting disease might be harmful to the patient's safety or avoid the patients from accomplishing the treatment(e.g serious hypertension, diabetes, thyroid dysfunction,active infection etc.).
- •History of neurological or psychiatric disorders, including epilepsy or dementia.
- •Severe infections within 4 weeks prior to first dose (eg, intravenous infusion of antibiotics, antifungal or antiviral drugs according to clinical protocols), or unexplained fever (T > 38.3 °C ) during screening or prior to first administration.
研究组 & 干预措施
Arm1
Experimental
Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
干预措施: Dalpiciclib (Drug)
Arm1
Experimental
Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
干预措施: Fulvestrant (Drug)
Arm1
Experimental
Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
干预措施: Pertuzumab (Drug)
Arm1
Experimental
Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
干预措施: Trastuzumab (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: 6 weeks
Progression free survival
次要结局
- Overall Survival (OS)(6 weeks)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(6 weeks)
- Objective response rate (ORR)(6 weeks)
- Clinical benefit rate (CBR)(6 weeks)
- Duration of remission (DoR)(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerResectable Biliary Tract CancerNCT05640791Tianjin Medical University Cancer Institute and Hospital40
进行中（未招募）
2 期
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI StatusNCT04053322UNICANCER172
尚未招募
2 期
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorHR+/HER2- Advanced Breast CancerNCT06556862Beijing 302 Hospital155
终止
1 期
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerRecurrent Gynecological CancerMetastatic Cervical CancerMetastatic Ovarian CancerMetastatic Vaginal CancerMetastatic Vulvar CancerMetastatic Endometrial CancerRecurrent Cervical CarcinomaRecurrent Ovarian CarcinomaRecurrent Vaginal CancerRecurrent Vulvar CancerRecurrent Endometrial CancerNCT03277482Dana-Farber Cancer Institute16
终止
1 期
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaNCT03522584University of Washington6